Psychological strategies for discontinuing benzodiazepine treatment

Journal of Clinical Psychopharmacology

Volumn 19, Issue 6 SUPPL. 2, 1999, Pages

  Spiegel, David A ^a  

^a BOSTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE DERIVATIVE;

ANXIETY NEUROSIS; CONFERENCE PAPER; DRUG DEPENDENCE; DRUG WITHDRAWAL; HUMAN; PANIC; PRIORITY JOURNAL; TREATMENT INDICATION; TREATMENT PLANNING;

ANTI-ANXIETY AGENTS; BENZODIAZEPINES; HUMANS; PANIC DISORDER; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 0032724902     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-199912002-00004     Document Type: Conference Paper

References (38)

1. Schatzberg AF, Cole JO, DeBatista C. Manual of clinical psychopharmacology, 3rd ed. Washington, DC: American Psychiatric Press, 1997:223-38.
2. Schweizer E, Rickels K, Case WG, Greenblatt DJ. Long-term therapeutic use of benzodiazepines: II. Effects of gradual taper. Arch Gen Psychiatry 1990;47:908-15.
3. Rickels K, Case WG, Schweizer E, Garcia-Espana F, Fridman R. Benzodiazepine dependence: management of discontinuation. Psychopharmacol Bull 1990;26:63-8.
4. Schweizer E, Rickels K, Case WG, Greenblatt DJ. Carbamazepine treatment in patients discontinuing long-term benzodiazepine therapy. Arch Gen Psychiatry 1991;48:448-52.
5. Albeck JH. Withdrawal and detoxification from benzodiazepine dependence: a potential role for clonazepam. J Clin Psychiatry 1987;48[suppl]:43-8.
6. Sanchez-Craig M, Cappell H, Busto U, Kay G. Cognitive-behavioural treatment for benzodiazepine dependence: a comparison of gradual versus abrupt cessation of drug intake. Br J Addict 1987;82:1317-27.
7. Elsesser K, Sartory G, Maurer J. The efficacy of complaints management training in facilitating benzodiazepine withdrawal. Behav Res Ther 1996;34:149-56.
8. Tyrer P, Murphy S, Oates G, Kingdon D. Psychological treatment for benzodiazepine dependence. Lancet 1985;1:1042-3.
9. Higgitt A, Golombok S, Fonagy P, Lader M. Group treatment of benzodiazepine dependence. Br J Addict 1987;82:517-32.
10. Clark DM. A cognitive approach to panic. Behav Res Ther 1986; 24:461-70.
11. Ehlers A. Interaction of psychological and physiological factors in panic attacks. In: Lovibond PF, Wilson P, eds. Proceedings of the 24th congress of psychology: clinical and abnormal psychology. Amsterdam: Elsevier, 1989:1-14.
12. Ehlers A, Margraf J, Roth WT. Selective information processing, interoception, and panic attacks. In: Hand I, Wittchen H-U, eds. Panic and phobias 2: treatments and variables affecting course and outcome. Berlin: Springer, 1988:129-48.
13. McNally RJ, Foa EB. Cognition and agoraphobia: bias in the interpretation of threat. Cogn Ther Res 1987;11:567-81.
14. Harvey JM, Richards JC, Dziadosz T, Swindell A. Misinterpretation of ambiguous stimuli in panic disorder. Cogn Ther Res 1993;17:235-48.
15. Clark DM, Salkovskis PM, Öst L-G, Breitholz E, Koehler KA, Westling BE, Jeavons A, Gelder M. Misinterpretation of body sensations in panic disorder. J Consult Clin Psychol 1997;65:203-13.
16. Barlow DH, Craske MG. Mastery of your anxiety and panic II. Albany, NY: Graywind Publications, 1994.
17. Craske MG, Meadows E, Barlow DH. Therapist's guide for the Mastery of Your Anxiety and Panic II & Agoraphobia Supplement (MAP II) program. Albany, NY: Graywind Publications, 1994.
18. Shear MK. Acute treatment outcomes. In: Woods SW, chair. First-line treatment of panic disorder - cognitive behavior treatment vs. imipramine vs. their combination: a multi-center study. Symposium conducted at the meeting of the New Clinical Drug Evaluation Unit (NCDEU) Program, Boca Raton, FL, June 1998.
19. Gorman JM. Continuation treatment outcomes. In: Woods SW, chair. First-line treatment of panic disorder - cognitive behavior treatment vs. imipramine vs. their combination: a multi-center study. Symposium conducted at the meeting of the New Clinical Drug Evaluation Unit (NCDEU) Program, Boca Raton, FL, June 1998.
20. Barlow DH, Craske MG, Cerny JA, Klosko JS. Behavioral treatment of panic disorder. Behav Ther 1989;20:261-82.
21. Klosko JS, Barlow DH, Tassinari R, Cerny JA. A comparison of alprazolam and cognitive-behavior therapy in treatment of panic disorder. J Consult Clin Psychol 1990;58:77-84.
22. Craske MG, Brown TA, Barlow DH. Behavioral treatment of panic disorder: a two-year follow-up. Behav Ther 1991;22:289-304.
23. Klosko JS. Barlow DH, Tassinari R, Cerny JA. A comparison of alprazolam and behavior therapy in treatment of panic disorder [erratum]. J Consult Clin Psychol 1995;63:830.
24. Barlow DH, Lehman CL. Advances in the psychosocial treatment of anxiety disorders. Arch Gen Psychiatry 1996;53:727-35.
25. Telch MJ, Lucas JA, Schmidt NB, Hanna HH, Jaimez TS, Lucas RA. Group cognitive-behavioral treatment of panic disorder. Behav Res Ther 1993;31:279-87.
26. Otto MW, Pollack MH, Sachs GS, Reiter SR, Meltzer-Brody S, Rosenbaum JF. Discontinuation of benzodiazepine treatment: efficacy of cognitive-behavioral therapy for patients with panic disorder. Am J Psychiatry 1993;150:1485-90.
27. Spiegel DA, Bruce TJ, Gregg SF, Nuzzarello A. Does cognitive behavior therapy assist slow-taper alprazolam discontinuation in panic disorder? Am J Psychiatry 1994;151:876-81.
28. Bruce TJ, Spiegel DA, Hegel MT. Cognitive behavior therapy helps prevent relapse and recurrence of panic disorder following alprazolam discontinuation: a long-term follow-up of the Peoria and Dartmouth studies. J Consult Clin Psychol 1999;67:151-6.
29. Marks IM, Swinson RP, Basoglu M, Kuch K, Noshirvani H, O'Sullivan G, Lelliott PT, Kirby M, McNamee G, Sengun S, Wickwire K. Alprazolam and exposure alone and combined in panic disorder with agoraphobia: a controlled study in London and Toronto. Br J Psychiatry 1993;162:776-87.
30. Barry H III, Etheredge EE, Miller NE. Counterconditioning and extinction of fear fail to transfer from amobarbital to nondrug state. Psychopharmacology (Berl) 1965;8:150-6.
31. Sherman AR. Therapy of maladaptive fear-motivated behavior in the rat by the systematic gradual withdrawal of a fear-reducing drug. Behav Res Ther 1967;5:121-9.
32. Otto MW, Pollack MH, Sabatino SA. Maintenance of remission following cognitive behavior therapy for panic disorder: possible deleterious effects of concurrent medication treatment. Behav Ther 1996;27:473-82.
33. Reiss S, Peterson RA, Gursky M, McNally RJ. Anxiety sensitivity, anxiety frequency, and prediction of fearfulness. Behav Res Ther 1986;24:1-8.
34. Bruce TJ, Spiegel DA, Gregg SF, Nuzzarello A. Predictors of alprazolam discontinuation with and without cognitive behavior therapy in panic disorder. Am J Psychiatry 1995;152:1156-60.
35. Basoglu M, Marks IM, Kilic C, Brewin CR, Swinson RP. Alprazolam and exposure for panic disorder with agoraphobia: attribution of improvement to medication predicts subsequent relapse. Br J Psychiatry 1994;164:652-9.
36. Spiegel DA, Bruce TJ. Benzodiazepines and exposure-based cognitive behavior therapies for panic disorder: conclusions from combined treatment trials. Am J Psychiatry 1997;154:773-80.
37. Barlow DH, Lehman CL. Advances in the psychosocial treatment of anxiety disorders: implications for national health care. Arch Gen Psychiatry 1996;53:727-35.
38. Barlow DH, Esler JL, Vitali AE. Psychosocial treatments for panic disorders, phobias, and generalized anxiety disorder. In: Nathan PE, Gorman JM, eds. A guide to treatments that work. New York: Oxford, 1998:288-318.